These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20006887)

  • 21. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
    Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
    Fowler JE; Bigler SA; Miles D; Yalkut DA
    J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
    Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
    Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
    Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
    BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
    van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH
    BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.
    Al-Ghamdi AM; Lockwood G; Toi A; Kulkarni GS; Evans A; Finelli A; Zlotta AR; Fleshner N
    J Urol; 2008 Apr; 179(4):1332-4. PubMed ID: 18289588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
    Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
    Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
    Elliott CS; Shinghal R; Presti JC
    J Urol; 2008 May; 179(5):1756-61; discussion 1761. PubMed ID: 18343425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and external validation of an extended repeat biopsy nomogram.
    Chun FK; Briganti A; Graefen M; Porter C; Montorsi F; Haese A; Scattoni V; Borden L; Steuber T; Salonia A; Schlomm T; Latchemsetty K; Walz J; Kim J; Eichelberg C; Currlin E; Ahyai SA; Erbersdobler A; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
    J Urol; 2007 Feb; 177(2):510-5. PubMed ID: 17222622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.